Nucor earnings beat by $0.08, revenue fell short of estimates
Peter Altman, President and CEO of BioCardia, Inc. (NASDAQ:BCDA), recently acquired a total of 600 shares of the company’s common stock in two separate transactions. The purchases, executed on April 10 and April 11, amounted to a total value of $1,206. The shares were bought at prices ranging from $1.99 to $2.03 per share, close to the current trading price of $1.98. The stock has experienced significant pressure, down 66% over the past year, with the company’s market capitalization now at $9.34 million.
Following these transactions, Altman now holds a total of 112,620 shares directly. These acquisitions reflect Altman’s ongoing investment in the company, which specializes in the development of biological products. BioCardia is headquartered in Sunnyvale, California. According to InvestingPro analysis, while the company maintains more cash than debt on its balance sheet, it’s currently rated as having WEAK financial health. Discover 12 additional key insights about BCDA and access comprehensive analysis with an InvestingPro subscription.
In other recent news, BioCardia, Inc. reported a significant reduction in expenses for the fourth quarter of 2024, with total expenses decreasing by 35% year-over-year. The company’s R&D expenses dropped by 43%, and SG&A expenses decreased by 16%, contributing to a net loss reduction to $7.9 million from $11.6 million in the previous year. BioCardia shared promising updates on its CardiAMP heart failure trial, with the CardiAMP Cell Therapy showing potential benefits in treating ischemic heart failure. Emory University has begun enrolling patients for the CardiAMP HF II trial, a pivotal Phase III study evaluating this therapy. The CardiAMP therapy, which has received FDA Breakthrough Designation, involves using a patient’s own bone marrow cells to stimulate natural healing and has shown increased survival and improved quality of life in preliminary data. BioCardia is preparing for regulatory submissions and new trial activations, with ongoing discussions in the U.S. and Japan. The company’s strategic focus on advancing its product pipeline is underscored by its recent financial performance and trial developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.